A prostate-specific antigen (PSA)-activated vinblastine prodrug selectively kills PSA-secreting cells in vivo.

  title={A prostate-specific antigen (PSA)-activated vinblastine prodrug selectively kills PSA-secreting cells in vivo.},
  author={Deborah Defeo-Jones and Stephen F Brady and D. M. Feng and Bradly K Wong and Trina Bolyar and Kathleen Haskell and David M. Kiefer and Karen R. Leander and Elizabeth M. McAvoy and Patricia K Lumma and Joseph M Pawluczyk and Jenny M-C Wai and Sherri L. Motzel and Kevin Keenan and Matthew J van Zwieten and Jiunn Huei Lin and Victor M. Garsky and Roger M. Freidinger and Allen Oliff and Raymond E. Jones},
  journal={Molecular cancer therapeutics},
  volume={1 7},
Currently, there is no therapy for men with androgen-refractory prostate cancer that substantially extends survival. This report characterizes by in vitro and in vivo techniques a new chemotherapeutic that is composed of desacetyl-vinblastine covalently linked to a peptide that contains a peptide bond that can be hydrolyzed by prostate-specific antigen (PSA). This compound (referred to as vinblastine-conjugate) is minimally toxic to cells in culture which do not express PSA. In the presence of… CONTINUE READING
16 Extracted Citations
19 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 16 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 19 references

A phase I and II trial of a psa activated peptide-doxorubicin conjugate, with and without prednisone, in patients with hormone refractory prostate cancer

  • R. S. DiPaola, J. Rinehart, +11 authors S. Yao
  • Am. Soc. Clin. Oncol., Abs 727,
  • 2001

- specific antigen ( PSA or hK 3 ) : substrate specificity and regulation by Zn ( 2  ) , a tight - binding inhibitor

  • A. Christensson, C. Laurell, H. Lilja
  • 2000

cancer xenografts

  • E. Diamandis, H. Yu, D. J. A. Sutherland
  • 2000

Similar Papers

Loading similar papers…